DPP9–KEAP1 Redox Control of Inflammasome Signaling

The 2025 Journal of Biological Chemistry research article, The serine protease DPP9 and the redox sensor KEAP1 form a mutually inhibitory complex, addresses a major unresolved question in innate immune regulation: how intracellular stress might connect DPP9 activity with redox sensing and inflammasome activation. The study is especially important because synthetic DPP9 inhibitors are known to activate NLRP1 and CARD8 inflammasomes, whereas a physiologically relevant endogenous DPP9 inhibitor had not been identified. The authors provide evidence for such a regulatory mechanism through KEAP1, the principal cellular sensor that controls NRF2 stability. The reference paper is available through its published article record.

Study Background and Research Question

Inflammasomes are multiprotein signaling platforms that activate caspase-1, promote maturation of interleukin-1β and interleukin-18, and cleave gasdermin D to produce pyroptotic cell death. NLRP1 and CARD8 are unusual inflammasome sensors because their activation involves proteasomal removal of an autoinhibitory N-terminal fragment. Their inflammatory C-terminal fragments can then be stabilized or released depending on the state of a ternary complex containing full-length sensor protein and DPP9.

DPP9 is a serine protease that removes N-terminal Xaa-Pro dipeptides from substrates, but its critical physiological substrates remain incompletely defined. Synthetic inhibitors such as Val-boroPro activate NLRP1 and CARD8, suggesting that endogenous inhibition or conformational regulation of DPP9 could act as a danger signal. At the same time, redox-linked proteotoxic stress accelerates degradation of the N-terminal fragment of NLRP1. These observations led the authors to ask whether a redox-regulated protein could bind DPP9 and provide a molecular connection between oxidative stress, DPP9 inhibition, and inflammasome readiness, as described in the reference study.

Key Innovation from the Reference Study

The central innovation is the identification of KEAP1 as a DPP9-binding protein that recognizes an inactive conformation of DPP9. Rather than simply blocking the active site, KEAP1 appears to stabilize DPP9 in a non-native state. This finding expands the concept of DPP9 regulation from classical enzymatic inhibition to conformational control.

The interaction is reciprocal. DPP9 in the KEAP1-bound state inhibits KEAP1’s ability to bind and promote degradation of NRF2. As a result, NRF2 accumulates and activates an antioxidant transcriptional response. The paper therefore describes a mutually inhibitory complex: KEAP1 suppresses DPP9 function, while inactive DPP9 suppresses the KEAP1–NRF2 degradation pathway. This two-way relationship provides a plausible molecular bridge between intracellular redox status and innate immune signaling without claiming that KEAP1 alone is the missing inflammasome trigger.

A second conceptual advance is the observation that DPP9 conformation is experimentally plastic. The authors report that newly synthesized DPP9 and chemically denatured DPP9 can be driven toward a KEAP1-binding state, whereas the folded dimeric form is less accessible to KEAP1. The danger-associated stimulus that causes this transition under physiological conditions remains unknown, but the result establishes a testable model for discovering additional DPP9 regulators.

Methods and Experimental Design Insights

The experimental strategy combined protein-interaction analysis, biochemical reconstitution, conformational perturbation, and cell-based functional readouts. This design is valuable because it separates three questions that are often conflated: whether two proteins interact, whether the interaction changes enzymatic state, and whether the altered complex affects a cellular signaling pathway.

• Interaction mapping: The authors searched for proteins that associate with DPP9 and focused on KEAP1 as a candidate redox-linked binding partner. Follow-up biochemical experiments tested whether the interaction was compatible with a specific DPP9 conformational state rather than being a nonspecific consequence of protein aggregation.
• Conformational perturbation: The study compared folded DPP9 with material produced under conditions of new protein expression or chemical denaturation. These perturbations were used to examine whether DPP9 transitions into a KEAP1-binding state. This approach is particularly informative for proteins whose function depends on oligomerization and structural stability.
• Functional enzymology: DPP9 activity and KEAP1 binding were evaluated together rather than treating physical association as proof of inhibition. The resulting evidence supports the interpretation that KEAP1 binds an inactive or altered form of DPP9.
• NRF2 pathway analysis: Cellular assays examined whether DPP9–KEAP1 association changed KEAP1-dependent NRF2 binding and degradation. NRF2 accumulation or antioxidant-response induction was interpreted as a functional consequence of impaired KEAP1 activity, not merely as a marker of protein interaction.
• Mechanistic controls: Comparing native, newly expressed, and chemically perturbed DPP9 provides a useful framework for distinguishing a stable physiological complex from an artifact caused by overexpression or unfolding. Similar studies should include matched expression, folding, and degradation controls.

Protocol Parameters

• DPP9 conformational state: Compare folded dimeric DPP9 with experimentally perturbed material when testing KEAP1 binding; the reference study identifies conformational state as a key variable.
• Interaction readout: Pair a physical binding measurement with a DPP9 activity assay so that association is not mistaken for functional inhibition.
• NRF2 response: Measure KEAP1-dependent NRF2 stability or transcriptional output alongside DPP9–KEAP1 interaction data to connect biochemistry with cell-level function.
• Inflammasome interpretation: Do not infer NLRP1 or CARD8 activation from NRF2 induction alone. Direct inflammasome, caspase-1, cytokine, or gasdermin-D readouts are required for that conclusion.
• Workflow recommendation: Use native-protein, altered-folding, and vehicle controls in parallel, and report whether observed effects depend on protein abundance, folding state, or cellular stress.

Core Findings and Why They Matter

The first major finding is that KEAP1 can bind DPP9 in an inactive conformation. This provides the first clear example in the study of a non-synthetic molecular mechanism capable of suppressing DPP9. It also explains why simply measuring DPP9 abundance may be insufficient: functional activity depends on structural state and oligomeric context.

The second finding is that DPP9 binding compromises KEAP1’s canonical regulation of NRF2. The resulting antioxidant response places DPP9 within a redox-sensitive feedback system. In this model, cellular conditions that alter protein folding or the intracellular reducing environment could influence both DPP9 activity and NRF2 signaling. The paper does not establish which physiological danger signal initiates the transition, but it narrows the search to mechanisms that control DPP9 conformation or stability.

The third finding is conceptual rather than merely descriptive. NLRP1 regulation already links proteotoxic and redox stress to inflammasome activation, while DPP9 restrains inflammatory sensor fragments. By demonstrating that DPP9 is directly coupled to KEAP1, the study offers a unified framework in which redox stress, protein quality control, antioxidant signaling, and inflammasome competence can be investigated together. Importantly, the work supports a mechanistic hypothesis rather than a complete pathway: the endogenous signal that converts DPP9 into a KEAP1-binding state still needs to be identified.

Comparison with Existing Internal Articles

The available internal literature focuses primarily on experimental perturbation of mitochondrial stress, apoptosis, and autophagy. For example, the internal mitochondrial perturbation guide emphasizes assay design, reproducibility, and interpretation of stress-associated phenotypes. That resource is complementary to the reference paper: it addresses how researchers can generate and measure cellular stress, whereas Tsamouri, Hsiao, and Bachovchin define a protein-level mechanism that may determine how redox stress is sensed and translated into signaling.

Why this cross-domain matters, maturity, and limitations

Connecting mitochondrial or oxidative stress workflows to DPP9–KEAP1 biology may help researchers ask whether a stress phenotype changes DPP9 conformation, KEAP1 activity, NRF2 output, or inflammasome competence. However, this cross-domain connection remains mechanistic and provisional. The reference study does not show that every mitochondrial perturbation produces the KEAP1-binding form of DPP9, and a stress-induced NRF2 response cannot by itself establish NLRP1 or CARD8 activation. Direct biochemical and inflammasome-specific validation is therefore essential.

Limitations and Transferability

The most important limitation is that the physiological trigger for DPP9 conversion into a KEAP1-binding state remains unidentified. Experimental induction through protein expression conditions or chemical denaturation demonstrates structural possibility, but it does not define the endogenous process operating during infection, proteotoxic stress, or oxidative imbalance.

Transferability also depends on cellular context. DPP9, KEAP1, NRF2, NLRP1, and CARD8 may differ in abundance, compartmentalization, and regulatory state among cell types. A result observed in a reconstituted protein system may not reproduce in primary immune cells, and an NRF2 response may reflect antioxidant compensation without causing pyroptosis. Researchers should therefore distinguish direct binding, enzymatic inhibition, NRF2 pathway activation, and inflammasome output as separate experimental endpoints.

Finally, the study establishes a strong mechanistic relationship but does not identify all relevant DPP9 substrates or determine whether KEAP1 binding is sufficient to activate NLRP1 or CARD8. Future work should remain focused on testing the already proposed links among DPP9 conformation, KEAP1–NRF2 regulation, redox state, and inflammasome control rather than assuming that the pathway is complete.

Research Support Resources

For complementary cellular stress workflows, researchers can use Rotenone (SKU B5462), a mitochondrial Complex I inhibitor, to support studies of mitochondrial redox stress, autophagy pathway research, a caspase activation assay, a Parkinson's disease model, or broader neurodegenerative disease research. These applications provide perturbation tools for related stress phenotypes but should not be treated as direct evidence of DPP9–KEAP1 binding or inflammasome activation.